Search

Your search keyword '"Schröder, Carolina P."' showing total 163 results
Start Over Author "Schröder, Carolina P."
163 results on '"Schröder, Carolina P."'

2. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

Author

Eisses, Bertha, van Geel, Jasper J.L., Brouwers, Adrienne H., Bensch, Frederike, Elias, Sjoerd G., Kuip, Evelien J.M., Jager, Agnes, van der Vegt, Bert, Lub-de Hooge, Marjolijn N., Emmering, Jasper, Arens, Anne I.J., Zwezerijnen, Gerben J.C., Vugts, Daniëlle J., Menke-van der Houven van Oordt, C. Willemien, de Vries, Elisabeth G.E., Schröder, Carolina P., Bensch, F., van Es, S., van Essen-Eisses, B., and Boers, J.

Published
2024
Full Text
View/download PDF

3. Figure S6 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Data 1 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

5. Data from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

6. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, additional, Cuypere, Eveline, additional, Dalenc, Florence, additional, Dirix, Luc, additional, Chan, Steve, additional, Marme, Frederik, additional, Schröder, Carolina P., additional, Huober, Jens, additional, Duhoux, Francois P., additional, Vuylsteke, Peter, additional, Jager, Agnes, additional, Brain, Etienne, additional, Kuemmel, Sherko, additional, Pápai, Zsuzsanna, additional, Menke-van der Houven van Oordt, Catharina Willemien, additional, Perjesi, Luca, additional, Mueller, Christian, additional, Brignone, Chrystelle, additional, and Triebel, Frederic, additional

Published
2023
Full Text
View/download PDF

7. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Author

Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.

Subjects
METASTATIC breast cancer, LOBULAR carcinoma, EPIDERMAL growth factor receptors, METASTASIS, HISTOPATHOLOGY, POSITRON emission tomography
Abstract

Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Author

Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J. M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., and de Vries, Elisabeth G. E.

Published
2018
Full Text
View/download PDF

10. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer

Author

van Geel, Jasper J L, Boers, Jorianne, Elias, Sjoerd G, Glaudemans, Andor W J M, de Vries, Erik F J, Hospers, Geke A P, van Kruchten, Michel, Kuip, Evelien J M, Jager, Agnes, Menke-van der Houven van Oordt, Willemien C, van der Vegt, Bert, de Vries, Elisabeth G E, Schröder, Carolina P, Translational Immunology Groningen (TRIGR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Medical Oncology, Internal medicine, and CCA - Imaging and biomarkers

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer Research, SDG 3 - Good Health and Well-being, Oncology
Abstract

PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis. METHODS In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to qualitative whole-body [18F]FES-PET evaluation and quantitative [18F]FES uptake in the corresponding metastasis. A review and meta-analysis regarding [18F]FES-PET diagnostic performance were performed. RESULTS Whole-body [18F]FES-PET assessment predicted ER expression in the biopsied metastasis with good accuracy: a sensitivity of 95% (95% CI, 89 to 97), a specificity of 80% (66 to 89), a positive predictive value (PPV) of 93% (87 to 96), and a negative predictive value (NPV) of 85% (72 to 92) in 181 of 200 evaluable patients. Quantitative [18F]FES uptake predicted ER immunohistochemistry in the corresponding metastasis with a sensitivity/specificity of 91%/69% and a PPV/NPV of 90%/71% in 156 of 200 evaluable patients. For bone metastases, PPV/NPV was 92%/81%. Meta-analysis with addition of our data has increased diagnostic performance and narrowed the 95% CIs compared with previous studies with a sensitivity/specificity of both 86% (81 to 90 and 73 to 93, respectively). CONCLUSION In this largest prospective series so far, we established the clinical validity of [18F]FES-PET to determine tumor ER status in MBC. In view of the high diagnostic accuracy of qualitatively assessed whole-body [18F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332 ).

Published
2022

12. Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

Author

Mammatas, Lemonitsa H., Venema, Clasina M., Schröder, Carolina P., de Vet, Henrica C. W., van Kruchten, Michel, Glaudemans, Andor W. J. M., Yaqub, Maqsood M., Verheul, Henk M. W., Boven, Epie, van der Vegt, Bert, de Vries, Erik F. J., de Vries, Elisabeth G. E., Hoekstra, Otto S., Hospers, Geke A. P., and der Houven van Oordt, C. Willemien Menke-van

Published
2020
Full Text
View/download PDF

13. Supplementary Figure Legend from Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Author

Arjaans, Marlous, primary, Oude Munnink, Thijs H., primary, Oosting, Sjoukje F., primary, Terwisscha van Scheltinga, Anton G.T., primary, Gietema, Jourik A., primary, Garbacik, Erik T., primary, Timmer-Bosscha, Hetty, primary, Lub-de Hooge, Marjolijn N., primary, Schröder, Carolina P., primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Author

Arjaans, Marlous, primary, Oude Munnink, Thijs H., primary, Oosting, Sjoukje F., primary, Terwisscha van Scheltinga, Anton G.T., primary, Gietema, Jourik A., primary, Garbacik, Erik T., primary, Timmer-Bosscha, Hetty, primary, Lub-de Hooge, Marjolijn N., primary, Schröder, Carolina P., primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

17. sj-docx-1-tam-10.1177_17588359231170738 – Supplemental material for Molecular imaging as biomarker for treatment response and outcome in breast cancer

Author

van Geel, Jasper J. L., de Vries, Erik F. J., van Kruchten, Michel, Hospers, Geke A. P., Glaudemans, Andor W. J. M., and Schröder, Carolina P.

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359231170738 for Molecular imaging as biomarker for treatment response and outcome in breast cancer by Jasper J. L. van Geel, Erik F. J. de Vries, Michel van Kruchten, Geke A. P. Hospers, Andor W. J. M. Glaudemans and Carolina P. Schröder in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

18. Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice

Author

Waaijer, Stijn J. H., primary, Suurs, Frans V., additional, Hau, Cheei-Sing, additional, Vrijland, Kim, additional, de Visser, Karin E., additional, de Groot, Derk Jan A., additional, de Vries, Elisabeth G. E., additional, Lub-de Hooge, Marjolijn N., additional, and Schröder, Carolina P., additional

Published
2021
Full Text
View/download PDF

19. Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer

Author

Boers, Jorianne, primary, Loudini, Naila, additional, de Haas, Robbert J., additional, Willemsen, Antoon T. M., additional, van der Vegt, Bert, additional, de Vries, Elisabeth G. E., additional, Hospers, Geke A. P., additional, Schröder, Carolina P., additional, Glaudemans, Andor W. J. M., additional, and de Vries, Erik F. J., additional

Published
2021
Full Text
View/download PDF

20. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.

Author

van Geel, Jasper J.L., Boers, Jorianne, Elias, Sjoerd G., Glaudemans, Andor W.J.M., de Vries, Erik F.J., Hospers, Geke A.P., van Kruchten, Michel, Kuip, Evelien J.M., Jager, Agnes, Menke-van der Houven van Oordt, Willemien C., van der Vegt, Bert, de Vries, Elisabeth G.E., Schröder, Carolina P., and IMPACT-Metastatic Breast Consortium

Published
2022
Full Text
View/download PDF

21. Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study

Author

Ormel, Harm L., primary, Schröder, Carolina P., additional, van der Schoot, Gabriela G.F., additional, Westerink, Nico-Derk L., additional, van der Velden, Annette W.G., additional, Poppema, Boelo, additional, Vrieling, Aline H., additional, Gietema, Jourik A., additional, Walenkamp, Annemiek M.E., additional, and Reyners, Anna K.L., additional

Published
2021
Full Text
View/download PDF

22. Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor

Author

de Ruijter, Laura Kist, primary, van de Donk, Pim P., additional, Hooiveld-Noeken, Jahlisa S., additional, Giesen, Danique, additional, Ungewickell, Alexander, additional, Fine, Bernard M., additional, Williams, Simon P., additional, Bohorquez, Sandra M. Sanabria, additional, Yadav, Mahesh, additional, Koeppen, Hartmut, additional, Jing, Jing, additional, Guelman, Sebastian, additional, Lin, Mark T., additional, Mamounas, Michael J., additional, Eastham, Jeffrey, additional, Kimes, Patrick K., additional, Glaudemans, Andor W., additional, Brouwers, Adrienne H., additional, Lub-de Hooge, Marjolijn N., additional, Gietema, Jourik A., additional, Schröder, Carolina P., additional, Timens, Wim, additional, Jalving, Mathilde, additional, Elias, Sjoerd, additional, Oosting, Sjoukje F., additional, de Groot, Derk J., additional, and de Vries, Elisabeth G., additional

Published
2021
Full Text
View/download PDF

28. Molecular Imaging of the Receptor HER2 and the Ligand VEGF as Role Models for the Use of ImmunoPET in Drug Development

Author

Gaykema, Sietske B. M., primary, de Vries, Elisabeth G. E., additional, Oude Munnink, Thijs H., additional, Nagengast, Wouter B., additional, Terwisscha van Scheltinga, Anton G. T., additional, Hospers, Geke A. P., additional, Dierckx, Rudi A. J. O., additional, Brouwers, Adrienne H., additional, Schröder, Carolina P., additional, and Lub-de Hooge, Marjolijn N., additional

Published
2012
Full Text
View/download PDF

31. Assessment of Bone Lesions with18F-FDG PET Compared with99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management

Author

van Es, Suzanne C., primary, Velleman, Ton, additional, Elias, Sjoerd G., additional, Bensch, Frederike, additional, Brouwers, Adrienne H., additional, Glaudemans, Andor W.J.M., additional, Kwee, Thomas C., additional, Iersel, Marleen Woltman-van, additional, Maduro, John H., additional, Oosting, Sjoukje F., additional, de Vries, Elisabeth G.E., additional, and Schröder, Carolina P., additional

Published
2020
Full Text
View/download PDF

35. Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Author

Dirix, Luc, primary, Wildiers, Hans, additional, Huizing, Manon T, additional, De Cuypere, Eveline, additional, Schröder, Carolina P, additional, Armstrong, Anne C, additional, Huober, Jans, additional, Marmé, Frederik, additional, Schneeweiss, Andreas, additional, Khan, Sarah, additional, and Triebel, Fréderic, additional

Published
2020
Full Text
View/download PDF

36. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition

Author

Boers, Jorianne, primary, Venema, Clasina M., additional, de Vries, Erik F.J., additional, Glaudemans, Andor W.J.M., additional, Kwee, Thomas C., additional, Schuuring, Ed, additional, Martens, John W.M., additional, Elias, Sjoerd G., additional, Hospers, Geke A.P., additional, and Schröder, Carolina P., additional

Published
2020
Full Text
View/download PDF

37. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results

Author

van Es, Suzanne C., primary, van der Vegt, Bert, additional, Bensch, Frederike, additional, Gerritse, Sophie, additional, van Helden, Erik J., additional, Boon, Eline, additional, Angus, Lindsay, additional, Overbosch, Jelle, additional, Menke-van der Houven van Oordt, Catharina W., additional, Verheul, Henk M., additional, van Herpen, Carla M.L., additional, Jager, Agnes, additional, Oosting, Sjoukje F., additional, de Vries, Elisabeth G.E., additional, and Schröder, Carolina P., additional

Published
2019
Full Text
View/download PDF

38. Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer

Author

Koch, Maximillian, de Jong, Johannes S, Glatz, Jürgen, Symvoulidis, Panagiotis, Lamberts, Laetitia E, Adams, Arthur, Kranendonk, Mariëtte E G, Terwisscha van Scheltinga, Anton G T, Aichler, Michaela, Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N, Schröder, Carolina P, Jorritsma-Smit, Annelies, Linssen, Matthijs D, de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B, Elias, Sjoerd G, Oliveira, Sabrina, Witkamp, Arjen, Mali, Willem P Th M, van der Wall, Elsken, Garcia-Allende, Beatriz P, Van Diest, Paul J, de Vries, Elisabeth G, Walch, Axel, van Dam, Gooitzen M, Ntziachristos, Vasilis, Celbiologie, Sub Cell Biology, Pharmaceutics, Celbiologie, Sub Cell Biology, Pharmaceutics, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Microbes in Health and Disease (MHD), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Subjects
0301 basic medicine, Cancer Research, Pathology, medicine.medical_specialty, Fluorescence-lifetime imaging microscopy, Biodistribution, Indoles, Bevacizumab, SURGERY, INDOCYANINE GREEN, Antineoplastic Agents, Breast Neoplasms, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, In vivo, Image Interpretation, Computer-Assisted, Taverne, Journal Article, Medicine, Humans, HEAD, MARGINS, Aged, Fluorescent Dyes, AGENT, business.industry, Benzenesulfonates, Optical Imaging, Cancer, Histology, Middle Aged, medicine.disease, Molecular Imaging, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, SAFETY, Female, Molecular imaging, business, Indocyanine green, medicine.drug, FOLATE
Abstract

In vivo tumor labeling with fluorescent agents may assist endoscopic and surgical guidance for cancer therapy as well as create opportunities to directly observe cancer biology in patients. However, malignant and nonmalignant tissues are usually distinguished on fluorescence images by applying empirically determined fluorescence intensity thresholds. Here, we report the development of fSTREAM, a set of analytic methods designed to streamline the analysis of surgically excised breast tissues by collecting and statistically processing hybrid multiscale fluorescence, color, and histology readouts toward precision fluorescence imaging. fSTREAM addresses core questions of how to relate fluorescence intensity to tumor tissue and how to quantitatively assign a normalized threshold that sufficiently differentiates tumor tissue from healthy tissue. Using fSTREAM we assessed human breast tumors stained in vivo with fluorescent bevacizumab at microdose levels. Showing that detection of such levels is achievable, we validated fSTREAM for high-resolution mapping of the spatial pattern of labeled antibody and its relation to the underlying cancer pathophysiology and tumor border on a per patient basis. We demonstrated a 98% sensitivity and 79% specificity when using labeled bevacizumab to outline the tumor mass. Overall, our results illustrate a quantitative approach to relate fluorescence signals to malignant tissues and improve the theranostic application of fluorescence molecular imaging. Cancer Res; 77(3); 623–31. ©2016 AACR.

Published
2017

40. First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner.

Author

Brouwers, Adrienne H., van Sluis, Joyce, van Snick, Johannes H., Schröder, Carolina P., Baas, Inge O., Boellaard, Ronald, Glaudemans, Andor W. J. M., Borra, Ronald J. H., Lammertsma, Adriaan A., Dierckx, Rudi A. J. O., and Tsoumpas, Charalampos

Subjects
TRASTUZUMAB, BREAST cancer, SCANNING systems, COINCIDENCE, HER2 positive breast cancer
Abstract

One important advantage of using LAFOV PET/CT for imaging SP 89 sp Zr-labelled monoclonal antibodies (mAbs), i.e., immunoPET, is the substantial increase in sensitivity compared with standard axial field-of-view (SAFOV) PET/CT systems, which may lead to a remarkable image quality improvement. This article is part of the Topical Collection on Image of the month Long axial field-of-view (LAFOV) PET/CT scanners have been introduced recently [[1]], which offer numerous advantages [[3]]. Both patients were informed about the study aims, procedures (one additional PET/CT scan on the same day with the planned PET/CT), and the need to acquire an additional low-dose CT scan. [Extracted from the article]

Published
2022
Full Text
View/download PDF

41. Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse

Author

Bensch, Frederike, Smeenk, Michaël M, van Es, Suzanne C, de Jong, Johan R, Schröder, Carolina P, Oosting, Sjoukje F, Lub-de Hooge, Marjolijn N, Menke-van der Houven van Oordt, C Willemien, Brouwers, Adrienne H, Boellaard, Ronald, de Vries, Elisabeth G E, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Abstract

Rationale: Knowledge on monoclonal antibody biodistribution in healthy tissues in humans can support clinical drug development. Molecular imaging with positron emission tomography (PET) can yield information in this setting. However, recent imaging studies have analyzed the behavior of single antibodies only, neglecting comparison across different antibodies. Methods: We compared the distribution of four 89Zr-labeled antibodies in healthy tissue in a retrospective analysis based on the recently published harmonization protocol for 89Zr-tracers and our delineation protocol. Results: The biodistribution patterns of 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab on day 4 after tracer injection were largely similar. The highest tracer concentration was seen in healthy liver, spleen, kidney and intestines. About one-third of the injected tracer dose was found in the circulation, up to 15% in the liver and only 4% in the spleen and kidney. Lower tracer concentration was seen in bone marrow, lung, compact bone, muscle, fat and the brain. Despite low tracer accumulation per gram of tissue, large-volume tissues, especially fat, can influence overall distribution: On average, 5-7% of the injected tracer dose accumulated in fat, with a peak of 19% in a patient with morbid obesity. Conclusion: The similar biodistribution of the four antibodies is probably based on their similar molecular structure, binding characteristics and similar metabolic pathways. These data provide a basis for a prospectively growing, online accessible warehouse of molecular imaging data, which enables researchers to increase and exchange knowledge on whole body drug distribution and potentially supports drug development decisions.

Published
2018

42. Consideration of breast cancer subtype in targeting the androgen receptor

Author

Venema, Clasina M., primary, Bense, Rico D., additional, Steenbruggen, Tessa G., additional, Nienhuis, Hilde H., additional, Qiu, Si-Qi, additional, van Kruchten, Michel, additional, Brown, Myles, additional, Tamimi, Rulla M., additional, Hospers, Geke A.P., additional, Schröder, Carolina P., additional, Fehrmann, Rudolf S.N., additional, and de Vries, Elisabeth G.E., additional

Published
2019
Full Text
View/download PDF

45. Molecular Imaging in Cancer Drug Development

Author

Waaijer, Stijn J.H., primary, Kok, Iris C., additional, Eisses, Bertha, additional, Schröder, Carolina P., additional, Jalving, Mathilde, additional, Brouwers, Adrienne H., additional, Lub-de Hooge, Marjolijn N., additional, and de Vries, Elisabeth G.E., additional

Published
2018
Full Text
View/download PDF

46. Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

Author

Bensch, Frederike, primary, Smeenk, Michaël M., additional, van Es, Suzanne C., additional, de Jong, Johan R., additional, Schröder, Carolina P., additional, Oosting, Sjoukje F., additional, Lub-de Hooge, Marjolijn N., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Brouwers, Adrienne H., additional, Boellaard, Ronald, additional, and de Vries, Elisabeth G.E., additional

Published
2018
Full Text
View/download PDF

47. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies

Author

Venema, Clasina M., primary, Mammatas, Lemonitsa H., additional, Schröder, Carolina P., additional, van Kruchten, Michel, additional, Apollonio, Giulia, additional, Glaudemans, Andor W.J.M., additional, Bongaerts, Alfons H.H., additional, Hoekstra, Otto S., additional, Verheul, Henk M.W., additional, Boven, Epi, additional, van der Vegt, Bert, additional, de Vries, Erik F.J., additional, de Vries, Elisabeth G.E., additional, Boellaard, Ronald, additional, Menke van der Houven van Oordt, Catharina W., additional, and Hospers, Geke A.P., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results